NL-OMON44583已完成不适用
An open-label, Phase I study to assess safety, tolerability, radiation dosimetry, and imaging properties of 89Zr-labelled girentuximab (89Zr-girentuximab) for in vivo detection of clear cell renal carcinoma (CCRC) by positron emission tomography (PET) using different PET imaging methodologies. - 89Zr-girentuximab dosimetry in CCRC study * ZIR-DOSE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •All patients must meet all of the following criteria:;- Written informed consent
- •- Male or female >50 years of age
- •- Clinical suspicion of CCRC, based on incidental imaging evidence of a renal mass, requiring further diagnostic work-up (incidentalomas), or patients with established diagnosis of CCRC requiring staging
- •- Life expectancy of at least 6 months
- •- Consent to practise contraception until end of study (7 days after 89Zr-girentuximab injection)
排除标准
- •A patient will be excluded from participation in the trial if one or more of the following criteria are met:;- Known hypersensitivity to girentuximab
- •- Known uncontrolled hyperthyreoidism
- •- Exposure to any experimental diagnostic or therapeutic drug within 30 days from the date of planned administration of 89Zr-girentuximab
- •- Exposure to any radiopharmaceutical within 30 days (corresponding to 8 half-lives of 89Zr) prior to the administration of 89Zr-girentuximab.
- •- Ongoing toxicity grade 2 from previous standard or investigational therapies (Common Terminology Criteria for Adverse Events [CTCAE] version 4.03)
- •- Planned (for the period between injection of 89Zr-girentuximab and imaging) antineoplastic therapies
- •- Established renal cell carcinomas of other histological entities than CCRC
- •- Known brain metastases
- •- Serious non-malignant disease (e.g. psychiatric, infectious, autoimmune or metabolic), that may interfere with the objectives of the study or with the safety or compliance of the subject, as judged by the investigator
- •- Pregnant or breast-feeding women. Female patients of childbearing potential or male patients with female partners of childbearing potential, unless willing to practice full and true sexual abstinence or being surgically/permanently sterile or with a history of hysterectomy for women, not willing to practice effective contraception by using: a non-oral, injected or implanted non-oestrogen progesterone based hormonal method, male condom, vaginal diaphragm, cervical cap, intrauterine device, during the study period and within a period of 28 days (corresponding to 8 half-lives of 89Zr) after receiving study drug.
- •11. Subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders)
研究者
相似试验
未知
1 期
Phase 1 study of DS-8895aAdvanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available.JPRN-jRCT2080222257DAIICHISANKYO Co.,Ltd.38
未知
1 期
Phase 1 study of DS-1123aAdvanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available.JPRN-jRCT2080223031DAIICHISANKYO Co.,Ltd.27
已完成
1 期
A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- tumor Activity of AZD9833 in Japanese Women with ER Positive, HER2 Negative Advanced Breast CancerAdvanced Breast CancerJPRN-jRCT2080225373AstraZeneca KK12
进行中（未招募）
1 期
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients with Advanced Solid MalignanciesAdvanced solid malignanciesJPRN-jRCT2031220106Yamaji Shigeyuki18
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080224133AstraZeneca12